Skip to main content
Premium Trial:

Request an Annual Quote

Israeli Personalized Medicine Center Gets $50M Donation

NEW YORK (GenomeWeb News) – The Weizmann Institute of Science has received a $50 million donation to fund operations at the new Israel National Center for Personalized Medicine (INCPM), which is located at the Weizmann campus in Rehovot, Israel.

The INCPM is focused on conducting research involving genomics, protein profiling, bioinformatics, and drug discovery to advance new personalized approaches to diagnosing, treating, and preventing diseases.

The American Committee for the Weizmann Institute of Science said today that Nancy and Stephen Grand committed the funding, and that the INCPM has incorporated the Grand name into its own.

Now named the Nancy and Stephen Grand INCPM, the center is a national consortium that serves Israel's life sciences research community, hospitals, and industry. It will engage in international collaborations and "[draw] upon Israel's diverse genetic pool comprised of populations from around the globe," the committee said.

The institute is composed of the Crown Institute for Genomics; the de Botton Institute for Protein Profiling; the Wohl Institute for Drug Discovery; and the Mantoux Bioinformatics Institute.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.